Closely-held restor3d, a leading personalized 3D-printed orthopedic company, will acquire all outstanding shares of Conformis (NASDAQ:CFMS) for $2.27 a share, which represents an approximate 96% premium to the closing...
Raymond James initiated coverage of Fusion Pharmaceuticals (NASDAQ:FUSN) with an “outperform” rating and $13 price target. The stock closed at $4.37 on June 22. Fusion is a precision oncology company that has built a...
Quipt Home Medical (NASDAQ:QIPT; TSXV:QIPT) received final approval to list its common shares on the Toronto Stock Exchange and will commence trading on the TSX at the market open on June 21 under the symbol, QIPT. With...
BTIG initiated coverage of Beyond Air (NASDAQ:XAIR) with a “buy” rating and $15 price target. The stock closed at $5.73 on June 14. Beyond Air is a medical device company that has developed a technology to turn room air...
Alliance Global Partners initiated coverage of UpHealth (NYSE:UPH) with a “buy” rating and price target of $4.30. The stock closed at $1.45 on June 8. UpHealth operates as a digital health services company in the...
Research Capital upgraded Profound Medical (NASDAQ:PROF; TSX:PRN) to “speculative buy” from “hold” and raised its price target to $17.25 from $10.90, after the AMA approved three new Category 1 CPT codes for prostate...
Research Capital remains bullish on the ability of Theralase Technologies’ (TSXV:TLT; OTCQB:TLTFF) Ruvidar to treat BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), given the “strong data that has...
SVB Securities upgraded Elevation Oncology (NASDAQ:ELEV) to “outperform” from “market perform” and raised its price target to $8 from $5, following the abstract release for EO-3021 (Claudin 18.2) ahead of ASCO. “This is...
Stifel upgraded eFFECTOR Therapeutics (NASDAQ:EFTR) to “buy” from “hold” and raised its price target to $7 from $1.30, saying the “zotatifin combo is emerging as an active and underappreciated asset in breast cancer.”...
Analysts for Cantor Fitzgerald and Brookline Capital Markets gave high marks to Hepion Pharmaceuticals’ (NASDAQ:HEPA) Phase 2a ATTITUDE NASH trial results, which met its primary and secondary endpoints as well as showed...